Progress of c-MET Signaling Pathway and TKIs in Non-small Cell Lung Cancer

Progress of c-MET Signaling Pathway and TKIs in Non-small Cell Lung Cancer

c-MET is considered a promising oncogenic driver in non-small cell lung cancer (NSCLC) after the discovery of epidermal growth factor receptor (EGFR) and anaplastic lymphoma kinase (ALK). MET activation including gene mutation, amplification and protein overexpression, all of these are potential the...

Full description

Bibliographic Details
Main Authors: Xiaoqing YU, Yanjun XU, Yun FAN
Format: Article
Language:zho
Published: Chinese Anti-Cancer Association; Chinese Antituberculosis Association 2017-04-01
Series:Chinese Journal of Lung Cancer
Subjects:
Lung neoplasms
c-MET
Amplification
Crizotinib
Online Access:http://dx.doi.org/10.3779/j.issn.1009-3419.2017.04.10

Internet

http://dx.doi.org/10.3779/j.issn.1009-3419.2017.04.10

Similar Items